Target intelligence / Profile preview

Histone deacetylase 1, Histone deacetylase 2, Histone deacetylase 3, Histone deacetylase 10 (HDAC1, HDAC2, HDAC3, HDAC10)

Target
HDAC1, HDAC2, HDAC3, HDAC10
Molecular classification
Enzyme, Histone modification, Transcriptional regulator, Class I (HDAC1, 2, 3) and class IIb (HDAC10, although HDAC10 has distinct properties)
01

Overview

Histone deacetylase 1, 2, 3, and 10 are zinc-dependent enzymes that remove acetyl groups from lysine residues on histone tails, promoting chromatin condensation and transcriptional repression. HDACs also modify various non-histone proteins, affecting cellular processes such as cell cycle progression, apoptosis, and DNA repair. While HDAC1, HDAC2, and HDAC3 belong to class I HDACs and are mostly nuclear, HDAC10 belongs to class IIb and has unique polyamine deacetylase activity. Aberrant activity or expression of these enzymes is implicated in cancer and other diseases, making them important therapeutic targets for HDAC inhibitors[2][3][4][6][7].

Other names
HDACsRPD3-like proteinsDeacetylasehistone deacetylaseclass I/II HDACs
02

Mechanism of action

Inhibitors bind the HDAC catalytic domain (often Zn2+-dependent), block deacetylation of histone and non-histone substrates, resulting in hyperacetylation and altered gene expression, commonly leading to cell cycle arrest, apoptosis, or differentiation in cancer cells[2][3][1]. HDAC10 is distinct in being a polyamine deacetylase, not a true histone deacetylase[4].

03

Biological functions

Regulation of gene expressionChromatin remodelingCell cycle controlCell differentiationApoptosisDNA repairDeacetylation of non-histone proteins
04

Disease associations

CancerNeurological/psychiatric disorders (e.g., schizophrenia)Inflammatory and immune disordersCardiovascular disease
05

Safety considerations

Myelosuppression (thrombocytopenia, neutropenia)Cardiotoxicity (QT prolongation, arrhythmias)Gastrointestinal disturbancesFatigueOff-target effects due to poor isoform selectivity
06

Interacting drugs

Vorinostat (SAHA)

6 more in the full profile.

07

Biomarkers

HDAC expression levels or activity (by immunohistochemistry or activity assays)Acetylation status of histones in tumor samples (e.g., acetylated H3, H4 as readouts for HDAC inhibition)Gene signatures indicating HDAC target engagement

Beyond the preview

Go deeper on Histone deacetylase 1, Histone deacetylase 2, Histone deacetylase 3, Histone deacetylase 10 (HDAC1, HDAC2, HDAC3, HDAC10).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Histone deacetylase 1, Histone deacetylase 2, Histone deacetylase 3, Histone deacetylase 10 (HDAC1, HDAC2, HDAC3, HDAC10).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call